CME

Hypogonadism is shown to be associated with decreased sexual desire or libido as well as association with various comorbidities, such as obesity, type II diabetes, hypertension and more. This condition is often underdiagnosed, misdiagnosed, or under reported. Moreover, there is a lack of understanding of the pathophysiology, etiology and epidemiology. This interview with Dr. Stuart B. Moss from The Eunice Kennedy Shriver National Institute of Child Health and Human Development will discuss this condition and appropriate treatment options.  To participate in additional CME activities on this subject visit ProvaEucation.com.

The rates of melanoma have risen the past 30 years, with about 76,100 new cases of melanoma estimated to be diagnosed in 2014 alone. Join us as Dr. Jeffrey S. Weber, Senior Member at Moffitt Cancer Center in Tampa, FL, discusses the clinical support for ipilimumab, interferon alpha, interleukin-2, and monoclonal antibodies against PD-1 and PD-L1 in the management of melanoma. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm

Psoriasis is a chronic inflammatory skin condition that is frequently associated with other systemic diseases. It affects about 2% of US adults and can significantly affect quality of life. The etiology includes genetic and environmental factors. Plaque psoriasis is the most common form. Join us as Dr. Alan Menter discusses current and emerging treatment strategies for managing patients with this condition, particularly moderate to severe disease.

Recently the FDA announced the approval of HPV testing as the primary screen for cervical cancer. This means HPV testing can now be used instead of cytology for screening. The FDA's decision has caused considerable discussion in scientific journals and in the media. Join us as Dr. Thomas C. Wright Jr. addresses some of the key issues and clinical data that helped form the FDA decision.

Breast cancer risk assessment and screening are not identical, an important difference for your patients to understand. A woman's risk factors need to be identified to be of value to you in helping her make very personal decisions regarding breast health. Join us as Dr. Edward Sauter discusses the range of breast cancer risk factors to be considered; as he addresses various breast cancer risk model algorithm tools and how to choose between them; and assesses the clinical value of intraductal approaches to evaluating atypical hyperplasia of the breast as part of the risk assessment continuum. Additional Resources:Click here to access the National Cancer Institute's Breast Cancer Risk Assessment Tool.

Melanoma is the most aggressive form of skin cancer and its incidence continues to increase dramatically. It is likely more than 76,000 new cases will be diagnosed in the US in 2014. This interview will discuss the history of chemotherapy in treating melanoma and what role chemotherapy may play, alone or in combination, in the era of immunotherapeutic agents and targeted therapy.

The American Society of Clinical Oncology 50th Annual Meeting held in Chicago provided updates in advancements in immunotherapy for patients with non-small cell lung cancer (NSCLC). Join us as Dr. Mohammad Jahanzeb and Dr. David Spigel discuss the future of immunotherapy as a potential treatment option for patients with NSCLC.

Age-related macular degeneration (AMD) is a leading cause of severe, irreversible vision impairment in the world. In persons older than 40 years of age, AMD causes approximately 46% of cases of severe visual loss. Several risk factors can increase the chances of developing AMD, which include smoking, hypertension, ethnicity, age, and family history.Join us as Dr. Neil Bressler discusses the diagnostic methods, as well as the therapeutic approaches to managing the spectrum of AMD. Dr. Bressler will also review the scientific literature regarding AMD in addition to the future applications of clinical innovations in treating AMD.

Even though significant research efforts for over the past 40 years have enabled profound changes in the approach and management of patients with advanced melanoma, the prognosis for patients remains poor. The NCI and ACS report that over 75,000 new cases of malignant melanoma were diagnosed in the US in 2011, and over 9,000 patients died from the disease. Melanoma has the fastest-rising incidence of any cancer, with an increase in the US from 1 in 1,500 in 1935 to a rate of 1 in 58 in 2011. Thus the importance of new information coming from clinical trials. Dr. Omid Hamid presents highlights from the American Society of Clinical Oncology (ASCO) 50th Annual Meeting with a focus on advances in melanoma: immunotherapy combinations and targeted therapies. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm

CME credits: 0.50 Valid until: 06/05/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6882Blindness and visual impairment are among the 10 most common causes of disability in the United States and are associated with shorter life expectancy and lower quality of life. Glaucoma is a major public health problem in this country and the disease is manifest as a progressive optic neuropathy that, if left untreated, leads to blindness. Treatments to slow the progression of the disease are available; however, at least half of those who have glaucoma are not receiving treatment because they are unaware of their condition. An important goal of current research is to develop methods of early diagnosis to detect the disease in the early stages, when treatment is most effective in minimizing irreversible vision loss. Join us as Dr. Henry Jampel discusses these issues with the key points including current and new diagnostic modalities for the diagnosis of glaucoma, as well as the use of pharmacologic, surgical, and laser therapies for the treatment of glaucoma. Number of Credits: .5 AMA PRA Category 1 Credits™ Original Release Date: 06/06/2014Expiration Date: 06/05/2015 Estimated time to complete the activity: 30 minutes

CME credits: 0.25 Valid until: 05/09/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6898Melanoma is the most aggressive form of skin cancer, and while it represents less than 10% of all skin cancers it is responsible for more than 75% of all skin cancer-related deaths. And its incidence continues to increase dramatically: data estimates 76,699 new cases of melanoma have been diagnosed and approximately 9,500 patients have died of the disease in the U.S. during 2013. Please join us as Dr. Omid Hamid addresses critical clinical issues surrounding managing this difficult disease. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm Resources: NCCN Guidelines: www.nccn.org Society for Immunotherapy in Cancer Guidelines: www.sitcancer.org Estimated time to complete activity: 15 minutes

CME credits: 0.25 Valid until: 05/05/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6936Many healthcare providers are deficient in the utilization of new treatment regimens, as well as the application of prophylactic treatment vs. episodic treatment to achieve optimal quality of life. The World Federation of Hemophilia (WFH) Treatment Guidelines Working Group noted that recent advances have created a substantial need for the guidelines to be updated. This interview will include new information on hemophilia care to help providers incorporate the new findings into practice. Estimated time to complete activity: 15 mins.

CME credits: 0.25 Valid until: 05/05/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6957The American Association for Cancer Research (AACR) 105th Annual Meeting in San Diego invited discussion on the continued progress of immunotherapy for people with melanoma. This interview will review practice-changing data in melanoma, as presented at the AACR annual meeting. In particular, Dr. Flaherty will review the immune-stimulating effects of anti-ctla-4 and anti-pd-1 treatments that are evolving to improve the lives of people with melanoma. As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm Estimated time to complete activity: 15 minutes

CME credits: 0.25 Valid until: 05/05/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6958The American Association for Cancer Research 105th Annual Meeting held in San Diego provided a unique opportunity to assess the emerging clinical value of immunotherapy for patients with non-small cell lung cancer (NSCLC). Join us as Dr. Mohammad Jahanzeb and Dr. Ramaswamy Govindan review findings supporting immunotherapy as a potential treatment option in NSCLC, and provide insight into what might unfold in the near future. Estimated time to complete activity: 15 Minutes

The American Association for Cancer Research 105th Annual Meeting held in San Diego provided a unique opportunity to assess the emerging clinical value of immunotherapy for patients with non-small cell lung cancer (NSCLC). Join us as Dr. Mohammad Jahanzeb and Dr. Ramaswamy Govindan review findings supporting immunotherapy as a potential treatment option in NSCLC, and provide insight into what might unfold in the near future.